Opioid Pharmacokinetics, Serum Predictability, and Expected Metabolites

DRUG	Half-Life (Hrs[A])	Time to Steady State (Hrs[A])	Metabolites	Time to Peak Conc. (Hrs[A])	Serum Predict-ability	Bioavailability	Serum Concentration (ng/mL)
BUPRENORPHINE / NALOXONE[44,45,46] (Suboxone)	24-42/2-12	120-294	Norbuprenorphine	1.53-1.72 / 0.77-0.81	Y	15% / 3%	8/2mg: 3.37+/-1.8 and 0.193+/-0.0912
TRANSDERMAL BUPRENORPHINE[48]	26	3 days	Norbuprenorphine	60	Y	15%	Mult. Dose: 10mcg/hr: 0.224 Single Dose: 5mcg/hr: 0.176, 10mcg/hr: 0.191, 20mcg/hr: 0.471
BUCCAL BUPRENORPHINE[48,49]	27.6+/-11.2	3 days	Norbuprenorphine	2.5-3	Y	46-65%	Mult. Dose: 60mcg: 0.077+/-0.020, 120mcg: 0.156+/-0.044, 180mcg: 0.216+/-0.106, 240mcg: 0.364+/-0.125 Single Dose: 75mcg: 0.17+/-0.30, 300mcg: 0.47+/-0.47, 1200mcg: 1.43+/-0.45
CODEINE [13,14,24]	2.5-3.5	12.5-17.5	Morphine, Norcodeine, Normorphine, Hydrocodone, Codeine 6-glucuronide	1-2	Y	Well absorbed	IR 180mg = 222.9 +/- 48.9
TRANSDERMAL FENTANYL [7,8,9,24]	16-25	72	Norfentanyl, 4-N-(N-propionylanilino) piperidine, 4-N-(N-hydroxypropionylanilino) piperidine, 1-(2-phenethyl)-4-N-(N-hydroxypropionylanilino) piperidine	24-72	Y	92%	25 mcg/hr = 0.6 +/-0.3 50mcg/hr = 1.4 +/- 0.5 75mcg/hr = 1.7 +/- 0.7 100mcg/hr = 2.5 +/- 1.2
TRANSBUCCAL, TRANSMUCOSAL SUBLINGUAL FENTANYL7**	14-19 (Onsolis) 2.6-11.7 (Fentora) 7 (Actiq) 5-13 (Abstral)	13-98	As above	0.75-4 (Onsolis) 0.58-0.78 (Fentora) 0.3-2 (Actiq) 0.25-1 (Abstral)	Y	Onsolis 71% Fentora 65% Actiq 47% Abstral 54%	800 mcg = 1.67* (Onsalis) 800 mcg = 1.59* (Fentora) 800 mcg = 1.03* (Actiq) 800 mcg = 1.42* (Abstral)
HYDROCODONE[15,16,17,24, 39,40,41]	3.8	19-22.5	Hydromorphone, Norcodeine, 6-beta-hydrocodol, 6-alpha-hydrocodol, 6-beta-hydromorphol, 6-alpha-hydromorphol, norhydrocodone	1.3	Y	Well absorbed	IR 10mg = 23.6ng +/-5.2
HEROIN [21,22,23,24]	~3 min. 1.7-5.3 min	~15 min.	6-acetylmorphine, Morphine, Morphine-3-glucuronide, Normorphine, 6-acetylmorphine 3-glucuronide, Normorphine glucuronide	10 minutes for I.M. dose[B]	Y	Diacetylmorphine undergoes complete presystemic metabolism to morphine after oral administration	112mcg/min for 5 min Heroin level = 57 ng/mL[C] 6-acetylmorphine level=15ng/mL[C]
HYDROMORPHONE [10,11,12,24]	2.5	12.5	Hydromorphone-3-glucuronide, Hydromorphone-3-glucoside, Dihydroisomorphine-6-glucuronide, Dihydroisomorphine-6-glucoside, Dihydroisomorphine, Dihrydromorphine[E]	48-60 min.	Y	24%	IR 48 mg = 19.7 +/- 4.04
LEVORPHANOL	1 dose: 11-16 Chronic: 30	72	3-glucuronide	approximately 1	?		
MEPERIDINE	~3.6	3-6 days	Normeperidine, meperidinic acid, normeperidinicacid	1-1.5	?	Variable: IM-57%	100 mg IM = 551 ng/mL
METHADONE [18,19,20,24]	24	~5 days	EDDP (2-ethyl-1,5-dimethyl-3,-3-diphenylpyrrolinium), EMDP (2-ethyl-5-methyl-3,3-diphenylpyraline)	2-4	Y	85%	Linear drug levels increase 260ng/mL for every 1mg/kg consumed
MORPHINE [4,5,6,24,25]	2-4	24	Morphine-3-glucuronide, Morphine-6-glucuronide, Normorphine, 7,8-dihydromorphinone, codeine (minor)	IR = 1 CR = 2-3	Y	20-40%	IR 40mg = 11.1 +/-8.4 CR 100mg = 36.9 +/-15.5
MORPHINE / NALTREXONE[43] (Embeda)	29	145-203	As above + 6-beta-naltrexol	7.5	Y	20-40%	lower Cmax and a higher Cmin than conventional immediate-release morphine at steady-state
OXYCODONE [1,2,3,24]	IV,IR=3.2 CR=4.5-8	IR: 17.5 CR: 24-36	Noroxycodone, Oxymorphone, Oxycodyl, Oxymorphol, Noroxycodyl	IR: 1.6 CR: 2.1-3.2	Y	60-87%	IV (0.14 mg/kg)=34-38 IR 20mg = 15.6 +/-4.4 CR 20mg = 15.1 +/-4.7
OXYMORPHONE[42]	IR = 7.2 -9.4hr ER 9.4 – 11.3	IR: 3-4 days ER: 3 days	Oxyorphone-3-glucuronide, 6-OH-oxymorphone	IR: 30mins ER: 3 hrs	Y	10%[F]	IR 20mg: 4.39 +/-1.72 ER 20mg: 2.54 +/-1.35
TAPENTADOL[47]	4	20-28	Tapentadol-O-glucoronide, desmethyl tapentadol, hydroxyl tapentadol	1.25-1.5	Y	32%	Cmax – 2.45 mcg/mL
TRAMADOL (M1 metabolite)[50]	IR: 5.6-6.7 (6.7-7) ER: 6.5-10 (7.5-11)	IR: 2 days ER: 4 days	O-desmethyltramadol (M1)	IR: 1-2.3 (1.5-2.4) ER: 4-12 (5.15)	Y	IR: 75% ER: 85-95%	100mg IR q6h: 592 (110) 200mg ER qd: 332-345 (70-95)

Developed by: Jeffrey Fudin, B.S., Pharm.D., FCCP.
Rev 02/2015 Ruth Perkins, B.S., M.A., Pharm.D., BCPS; Rev 02/2016 by Joseph Gottwald, PharmD Candidate

Footnotes for Table Above IR = Immediate Release Products, CR = Continuous Release products, SS = Steady State A-Hours, unless otherwise indicated B-Can detect heroin and 6-acetyl morphine within 10-15 minutes of parenteral administration C-Administered IV in a single patient over 180 minutes ** These products are not considered bioequivalent D-Cummulative amount of fentanyl release from patch dose in 24 hours.	E-hydromorphone is 7,8-dihydromorphinone: Please note that morphine metabolism to hydro- morphone has been confirmed in 8 mammals other than humans. There is only data that correlates the conversion of morphine to hydromorphone in humans.[29] F- the bioavailability of oxymorphone increases significantly in hepatically (up to 12 fold) and renally impaired (65% with creatinine clearance less than 30 ml/min) patients *peak concentrations

References to Opioid Pharmacokinetics and Expected Metabolites

1. Reder RF, Oshlack B, Miotto JB, Benziger DD, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther. 1996 Jan-Feb;18(1):95-105.
2. Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic-pharmacodynamic relationships of controlled release oxycodone. Clin Pharmacol Ther. 1996 Jan: 59(1):52-61.
3. Oxycodone - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
4. Christup LL, Sjogren P, Jensen NH, Banning AM, Elbaek K, Ersboll A. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine? J Pain Symptom Manage. 1999 Sep;18(3):164-173.
5. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty four hourly Kapanol compared to twelve-hourly Ms Contin in the treatment of severe cancer pain. Pain 69 (1997)295-302.
6. Morphine - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
7. Fentanyl - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2011.
8. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal Fentanyl for Cancer Pain. Anesthesiology 1993 Jan;78(1):36-43.
9. Ashburn MA,Odgden LL,Ahang J, et al. The pharmacokinetics of transdermal fentanyl delivered with and without heat. J Pain.2003 Aug;4(6):291-7.
10. Hagen N, Thirlwell MP, Dhaliwal HS,et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled release hydromorphone. J Clin Pharmacol 1995;35:37-44.
11. JJ Vallner, JT Stewart, JA Kotzan, EB Kirsten, and IL Honigberg. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. *Journal of Clinical Pharmacology*, 1981; 21:152-156.
12. Hydromorphone - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
13. Band CJ, Band PR, Deschamps M, et al. Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine contin) codeine. J Clin pharmacol 1994;34:938-943.
14. Codeine - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
15. Cone EJ, Darwin WD, Gorodetzky CW, and Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metabolism and Disposition. 1978 6(4):488-493.
16. Honigberg IL, Stewart JT. Radioimmunoassay of hydromorphone and hydrocodone in human plasma. J Pharm Sci. 1980 Oct;69(10):1171-3.
17. Hydrocodone - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
18. Wolff K, Rostami-Hodjegan A, Hay AWM, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction. 2000;95(12):1771-1783.
19. Wolff K, Sanderson M, Hay AWM, and Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clinical Chemistry. 1991; 37(2):205-209.
20. Methadone - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
21. Inturrisi CE, Max MB, Foley KM, et al. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 1984; 310:1213-7.
22. Rentsch, KM, Kullak-Ublick GA, Reichel C, et al. Arterial and venous pharmacokinetics of intravenous heroin subjects who are addicted to narcotics. Clin Pharm Ther. 2001 Sep;70(3):237-246.
23. Heroin - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2005.
24. McQuay HJ. "Opioid problems, and morphine metabolism and excretion." Pain Research and Nuffield Department of Anaesthetics University of Oxford, UK. 8 March 2005. <http://www.jr2.ox.ac.uk/bandolier/booth/painpag/wisdom/c14.html#RTFToC44>
25. Yeh SY, McQuinn RL, Gorodetzky CW. Biotransformation of morphine to dihydromorphinone and normorphine in the mouse, rat, rabbit, guinea pig, cat, dog, and monkey. Drug Metab Dispos. 1977 Jul-Aug;5(4):335-42.
26. Lalovic B. Kharasch E. Hoffer C. Risler L. Liu-Chen LY. Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical Pharmacology & Therapeutics. 79(5):461-79, 2006 May.
27. Kalso E. Oxycodone**.** *Journal of Pain & Symptom Management. 29(5 Suppl):S47-56, 2005 May.*
28. Darbari DS. Minniti CP. Rana S. van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease. American Journal of Hematology. 83(3):233-6, 2008 Mar.
29. Cone EJ, Heit HA, Caplan YH, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006 Jan-Feb;30(1):1-5.
30. Murray A. Hagen NA. Hydromorphone. Journal of Pain & Symptom Management. 29(5 Suppl):S57-66, 2005 May.
31. Hutchinson MR. Menelaou A. Foster DJ. Coller JK. Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology. 57(3):287-97, 2004 Mar.
32. Lugo RA. Satterfield KL. Kern SE. Pharmacokinetics of methadone. Journal of Pain & Palliative Care Pharmacotherapy. 19(4):13-24, 2005.
33. Prommer E. Oxymorphone: a review. [Review] [29 refs] [Journal Article. Review] Supportive Care in Cancer. 14(2):109-15, 2006 Feb.
34. Hydromorphone- MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
35. Meperidine - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008.
36. Propoxyphene - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2008
37. Latta, KS, Ginsber B, Barkin, RL. Meperidine: A Critical Review. American Journal of Therapeutics. (9) 53 – 68. 2002.
38. McNulty JP. Can levorphanol be used like methadone for intractable refractory pain? Journal of Palliative Medicine. November 2(10) 293-296 , 2007.
39. Baselt, R C. Disposition of Toxic Drugs and Chemicals in Man, Second Edition. Davis, Calif.: Biomedical Publications, 1982.
40. Physicians' Desk Reference, Forty-Eight Edition. Montvale, NJ: Medical Economics Data Production Company, 1994.
41. Goldberger, Bruce A. Opiates Abused Drugs Monograph Series. Ed. Caplan, Yale H. Irving, TX: Abbott Laboratories, 1994.
42. Endo professional Package Insert. Copyright © Endo Pharmaceuticals Inc. 2006
43. morphine/naltrexone - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2011.
44. buprenorphine/naloxone - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2011.
45. Mendelson J, Upton RA, Evrhart ET, et al. Bioavailabliity of sublingual buprenorphine. J Clin Pharmacol 1997; 37:31-37.
46. Kuhlman JJ, Lalani S, Magluilo J, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Analytical Toxicology 1996; 20: 369-378.
47. Tapentadol - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2011.
48. Buprenorphine - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2016.
49. Bai SA, Xiang Q, Finn A. Evaluation of Pharmacokinetics of single- and multiple-dose buprenorphine buccal film in healthy volunteers. Clin Ther. 2016 Feb;38(2):358-69.
50. Tramadol - MICROMEDEX® Healthcare Series, Thomson MICROMEDEX, Greenwood Village, Colorado Copyright © 1974-2016.